Talk:Caladrius Biosciences

Copyright problem removed

Prior content in this article duplicated one or more previously published sources. The material was copied from: http://www.prnewswire.com/news-releases/amorcyte-a-neostem-company-enrolls-first-patient-in-preserve-phase-2-trial-for-acute-myocardial-infarction-138032648.html. Copied or closely paraphrased material has been rewritten or removed and must not be restored, unless it is duly released under a compatible license. (For more information, please see "using copyrighted works from others" if you are not the copyright holder of this material, or "donating copyrighted materials" if you are.)

For legal reasons, we cannot accept copyrighted text or images borrowed from other web sites or published material; such additions will be deleted. Contributors may use copyrighted publications as a source of information, and, if allowed under fair use, may copy sentences and phrases, provided they are included in quotation marks and referenced properly. The material may also be rewritten, providing it does not infringe on the copyright of the original or plagiarize from that source. Therefore, such paraphrased portions must provide their source. Please see our guideline on non-free text for how to properly implement limited quotations of copyrighted text. Wikipedia takes copyright violations very seriously, and persistent violators will be blocked from editing. While we appreciate contributions, we must require all contributors to understand and comply with these policies. Thank you. Justlettersandnumbers (talk) 22:11, 16 September 2015 (UTC)

Can we add Why they did not carry on with AMR-001 (NBS10)

Maybe cost of therapy ? or more effective competition ? Annual reports may explain. - Rod57 (talk) 05:55, 8 January 2016 (UTC)

Please update/correct Caladrius Biosciences Wikipedia page

Hello,

I work for Caladrius Biosciences and would like to submit a request to the Wiki editors to update the Caladrius Biosciences Wikipedia page with the correct company information. The current company overview/description is very outdated on its Wiki page. As a publicly traded company, Caladrius is legally bound to submit company updates to the SEC on a quarterly basis. The company's most recent 10-K filing is linked below; Please see Part 1 for the company overview, which is best to be used as an overview of the company and its current product candidates.

https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000032001721000043/clbs-20201231.htm

Thank you,

Lauren Lulic Caladrius Biosciences, Inc. Associate Director, Corporate Marketing and Communications — Preceding unsigned comment added by LaurenLulicCLBS (talk • contribs) 15:41, 23 March 2021 (UTC)

LaurenLulicCLBS, you haven't specified any changes that you believe to be necessary, nor have you listed the independent reliable sources which might support any such change. I'm declining your request. If there are errors or omissions of verifiable fact in this page, please state them briefly here, together with details of the independent reliable sources which verify them. Justlettersandnumbers (talk) 20:19, 2 April 2021 (UTC)

Justlettersandnumbers, Would you be able to add in more information about the company and what it does? An independent article was written about the company on Seeking Alpha which includes a lot of detail about what the company does and its objectives. Article link: https://seekingalpha.com/article/4414270-checking-in-on-caladrius-biosciences

Copyright problem removed

Prior content in this article duplicated one or more previously published sources. The material was copied from: http://thejdca.org/practical-cure-project-update-caladrius-biosciences-inc-treg. Copied or closely paraphrased material has been rewritten or removed and must not be restored, unless it is duly released under a compatible license. (For more information, please see "using copyrighted works from others" if you are not the copyright holder of this material, or "donating copyrighted materials" if you are.)

For legal reasons, we cannot accept copyrighted text or images borrowed from other web sites or published material; such additions will be deleted. Contributors may use copyrighted publications as a source of information, and, if allowed under fair use, may copy sentences and phrases, provided they are included in quotation marks and referenced properly. The material may also be rewritten, providing it does not infringe on the copyright of the original or plagiarize from that source. Therefore, such paraphrased portions must provide their source. Please see our guideline on non-free text for how to properly implement limited quotations of copyrighted text. Wikipedia takes copyright violations very seriously, and persistent violators will be blocked from editing. While we appreciate contributions, we must require all contributors to understand and comply with these policies. Thank you. Justlettersandnumbers (talk) 20:05, 2 April 2021 (UTC)